SavedAdd your journal

Journals / Turkish Journal of Internal Medicine / 2021 / Cilt: 3 - Sayı: 3

Prevalence of Hepatitis B virus serological groups in rheumatoid arthritis and association of previous hepatitis B virus infection with demographic data and parenteral therapies

Koray AYAR
Ali ASAN
Orhan ONART
Mert TÜRK
Tulay Dilara DEMIRAY
Pages
109–115
Publication Date
2021-07-29
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Age in RA patients with and without previous HBV infection was 60.8±12.4 and 56.7±14.2 years, respectively(p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Introduction: The aim of this study is to determine the frequency of Hepatitis b virus (HBV) serological groups in Rheumatoid arthritis (RA) and to compare the demographic characteristics and frequency of parenteral therapies between patient groups with and without previous HBV infection.
📊
Key Findings & Data:All participants were divided into 3 serological groups (patients naive to HBV infection, previous HBV infection, vaccinated).
💡
Conclusion & Impact:Age in RA patients with and without previous HBV infection was 60.8±12.4 and 56.7±14.2 years, respectively(p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Rheumatoid arthritis · Hepatitis B · parenteral therapies

Abstract

Introduction: The aim of this study is to determine the frequency of Hepatitis b virus (HBV) serological groups in Rheumatoid arthritis (RA) and to compare the demographic characteristics and frequency of parenteral therapies between patient groups with and without previous HBV infection. Methods: Charts of RA patients were examined retrospectively. HBsAg, anti-HBc IgG, and anti-HBs test results were screened. All participants were divided into 3 serological groups (patients naive to HBV infection, previous HBV infection, vaccinated). Those with previous HBV infection were further divided into 3 serological subgroups (naturally immune, anti-HBc IgG positive only, chronic HBV infection). Findings were compared between RA patients with and without previous HBV infection. Results: Four hundred and fifty-one patients (female/male: 343/108) were included. The prevalence of patients naive to HBV infection, with previous HBV infection and vaccinated were 59.4%, 33.7%, and 6.9%, respectively. The prevalence of patients with naturally immune, anti-HBc IgG positive only, and chronic HBV infection were 25.7%, 4.4%, and 3.5%, respectively. Age in RA patients with and without previous HBV infection was 60.8±12.4 and 56.7±14.2 years, respectively(p

🔖

Cite This Article

AYAR, K., ASAN, A., ONART, O., TÜRK, M., DEMIRAY, T. D. (2021). Prevalence of Hepatitis B virus serological groups in rheumatoid arthritis and association of previous hepatitis B virus infection with demographic data and parenteral therapies. Turkish Journal of Internal Medicine, Cilt: 3 - Sayı: 3, 109–115. https://ajindex.com/articles/809036

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (10)

  1. Schweitzer A, Horn J, Mikolajczyk RT, Krause G, Ott JJ. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. Lancet. 2015;386(10003):1546-55
  2. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095-128
  3. Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, et al. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clinical microbiology and infection: the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2015;21(11):1020-6
  4. Ramiro S, Gaujoux-Viala C, Nam JL, Smolen JS, Buch M, Gossec L, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Annals of the rheumatic diseases. 2014;73(3):529-35
  5. Chiu YM, Lai MS, Chan KA. Commensurate incidence and outcomes of liver enzyme elevation between anti-tumor necrosis factor users with or without prior hepatitis B virus infections. PloS one. 2018;13(4):e0196210
  6. Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, et al. Prospective study of reactivation of hepatitis B virus in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. Journal of gastroenterology. 2011;46(4):556-64
  7. Chen YM, Chen HH, Huang WN, Chen YH, Hsieh TY, Yang SS, et al. Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb-positive rheumatoid arthritis patients: A long-term, real-world observation. International journal of rheumatic diseases. 2019;22(6):1145-51
  8. Yilmaz N, Karadag O, Kimyon G, Yazici A, Yilmaz S, Kalyoncu U, et al. Prevalence of hepatitis B and C infections in rheumatoid arthritis and ankylosing spondylitis: A multicenter countrywide study. European journal of rheumatology. 2014;1(2):51-4
  9. Mahroum N, Watad A, Tiosano S, Hejly A, Mahagna H, Waknin R, et al. Chronic hepatitis B viral infection among RA patients-a cross-sectional control study. Clinical rheumatology. 2019;38(5):1237-41
  10. Permin H, Aldershvile J, Nielsen JO. Hepatitis B virus infection in patients with rhe